News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stemline Therapeutics, Inc. (STML) Announces Oral Presentation of SL-401, a Clinical-Stage Targeted Therapy, Demonstrating Notable Preclinical Activity in an Additional Indication, Chronic Myeloid Leukemia (CML), at the 15th International Conference on CML



9/25/2013 9:13:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401, which is entering pivotal clinical trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML), has shown preclinical activity in an additional hematologic cancer indication, chronic myeloid leukemia (CML). Marina Konopleva, MD, PhD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, will present studies detailing SL-401's notable activity against CML primary blasts and cancer stem cells (CSCs) in animal models and in vitro at the European School of Hematology (ESH) International Chronic Myeloid Leukemia Foundation (ICMLF) 15th International Conference on CML – Biology and Therapy in Estoril, Portugal on September 26-29, 2013. SL-401 significantly reduced the growth of CML blasts, as well as CSCs, from patients with tyrosine kinase inhibitor (TKI)-resistant CML. In addition, the combination of SL-401 and the TKI, imatinib (Gleevec), had a significant synergistic effect on inhibiting the growth of primary CML cells from patients. SL-401 also prolonged the survival of mice inoculated with primary cells from a CML patient in blast crisis who was resistant to several TKIs.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES